Genprex Beheer

Beheer criteriumcontroles 3/4

De CEO Genprex is Ryan Confer, benoemd in Sep2016, heeft een ambtstermijn van 8.17 jaar. bezit rechtstreeks 0.19% van de aandelen van het bedrijf, ter waarde $ 7.37K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.2 jaar en 4.3 jaar.

Belangrijke informatie

Ryan Confer

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	8.2yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	3.2yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Aug 15

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Jun 14

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Feb 09

Genprex: Limited Clinical Data To Justify Risk

Nov 19

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Oct 27

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Jun 11

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

May 05

Genprex' stock jumps after corporate update

Feb 01

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Jan 13

Genprex completes manufacturing scale-up of lung cancer therapy

Dec 22

Analyse CEO-vergoeding

Hoe is Ryan Confer's beloning veranderd ten opzichte van Genprex's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$23m
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$28m
Dec 31 2023	n/a	n/a	-US$31m
Sep 30 2023	n/a	n/a	-US$31m
Jun 30 2023	n/a	n/a	-US$30m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$1m	US$393k	-US$24m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$21m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$1m	US$345k	-US$21m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$18m
Mar 31 2021	n/a	n/a	-US$19m
Dec 31 2020	US$1m	US$351k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$1m	US$300k	-US$11m
Sep 30 2019	n/a	n/a	-US$12m
Jun 30 2019	n/a	n/a	-US$11m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$2m	US$225k	-US$12m
Sep 30 2018	n/a	n/a	-US$10m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$3m
Dec 31 2017	US$585k	US$180k	-US$3m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Ryan redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de US markt.

Compensatie versus inkomsten: De vergoeding van Ryan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ryan Confer (42 yo)

8.2yrs

Tenure

US$1,135,943

Compensatie

Mr. Ryan M. Confer, M.S. has been the Chief Financial Officer of Genprex, Inc. since September 2016 and serves as its Chief Executive Officer, President and Director since May 08, 2024. Mr. Confer has serv...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Berger	Chief Medical Officer	3.2yrs	US$947.11k	0.048% $ 1.9k
Ryan Confer	President	8.2yrs	US$1.14m	0.19% $ 7.4k
David Schloss	Senior Vice President of Human Resources	2.8yrs	geen gegevens	geen gegevens
Thomas Gallagher	Senior Vice President of Intellectual Property & Licensing	4.2yrs	geen gegevens	geen gegevens
Suzanne Thornton-Jones	Senior Vice President of Regulatory Affairs & Quality	1.3yrs	geen gegevens	geen gegevens
Jack Roth	Chairman of Scientific & Medical Advisory Board	no data	geen gegevens	geen gegevens

3.2yrs

Gemiddelde duur

Ervaren management: Het managementteam van GNPX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ryan Confer	President	less than a year	US$1.14m	0.19% $ 7.4k
Jack Roth	Chairman of Scientific & Medical Advisory Board	no data	geen gegevens	geen gegevens
Brent Longnecker	Independent Director	4.7yrs	US$161.61k	0.024% $ 962.7
James E. Rothman	Strategic Advisor to the Board of Directors	12.3yrs	geen gegevens	geen gegevens
Pasi Antero Janne	Member of Scientific & Medical Advisory Board	no data	geen gegevens	geen gegevens
George Peoples	Member of Clinical Advisory Board	3.8yrs	geen gegevens	geen gegevens
Shu Kam Mok	Member of Scientific & Medical Advisory Board	no data	geen gegevens	geen gegevens
George Simon	Member of Scientific & Medical Advisory Board	no data	geen gegevens	geen gegevens
William Wilson	Independent Director	4.7yrs	US$151.16k	0% $ 0
Jose Antonio Toscano	Independent Non-Executive Chairman	4.7yrs	US$161.61k	0% $ 0
George Gittes	Member of Scientific Advisory Board	4yrs	geen gegevens	geen gegevens
Michael Morse	Member of Clinical Advisory Board	3.8yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GNPX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Genprex Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Genprex, Inc Announces Executive Changes

Genprex, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Genprex, Inc. Receives Notice from Nasdaq Regarding Non-Compliance with Stockholders' Equity Requirement

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer

Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Genprex, Inc. Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

New major risk - Shareholder dilution

No longer forecast to breakeven

New major risk - Financial position

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc Announces Executive Changes

New major risk - Shareholder dilution

Genprex, Inc., Annual General Meeting, Jun 18, 2024

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc. has completed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Insufficient new directors

Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

New major risk - Market cap size

Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics

Genprex Receives Non-Compliance Notice From Nasdaq

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Genprex, Inc. announced delayed 10-Q filing

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate

Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy in Non-Small Cell Lung Cancer

Genprex, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Price target increased to US$6.23

High number of new and inexperienced directors

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Price target increased to US$6.50

High number of new and inexperienced directors

Genprex, Inc. Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancercer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex, Inc. Announces Positive Preclinical Data for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System for Delivery of FAS DNA Plasmid to Treat Metastatic Colorectal Cancer

Genprex, Inc. to Accelerate Opening of Acclaim-1 Clinical Trial Sites

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

Genprex: Limited Clinical Data To Justify Risk

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Genprex, Inc.(NasdaqCM:GNPX) dropped from Russell 3000E Index

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$8.25

Forecast to breakeven in 2024

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

Genprex, Inc. Announces Formation of Clinical Advisory Board

Genprex' stock jumps after corporate update

Genprex, Inc. Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Genprex, Inc. Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

Genprex completes manufacturing scale-up of lung cancer therapy

Genprex, Inc Completes Manufacturing Technology Transfer for Novel Gene Therapy

Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. Appoints George K. Gittes to Its Scientific Advisory Board